Clinical trials: Antipsychotic Agents
Schizophrenia and Related Disorders, Drug Administration Schedule
"Extended" (Alternate Day) Antipsychotic Dosing
The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment.
- Conditions
- Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
- Trial name
- NCT04478838
- Testing
- Risperidone, Olanzapine, paliperidone
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Psychosis
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed…
- Conditions
- Schizophrenia, Psychosis, Mania, Pregnancy
- Trial name
- LAMP (NCT05766007)
- Where
- 6 sites in Nigeria
- Volunteers
- 168 people
- Sponsor
- University of Liverpool
Deprescriptions, Antidepressive Agents
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER…
- Conditions
- Deprescriptions, Antidepressive Agents, Antipsychotic Agents, Analgesics, Opioid
- Trial name
- PARTNER (NCT05842928)
- Testing
- PARTNER intervention, Control intervention
- Where
- 3 sites in Germany
- Volunteers
- 352 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Tardive Dyskinesia, Antipsychotic Agents
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist.
- Trial name
- NCT03287778
- Testing
- Pyridoxine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Weight Gain, Antipsychotic Agents
Clozapine Induced Weight Gain
Clozapine is prescribed to patients with psychosis in whom other treatments have not worked. Research has shown, however, that clozapine may be associated with weight gain and abnormal blood sugar levels in some patients.
- Conditions
- Weight Gain, Antipsychotic Agents, Pharmacogenetics
- Trial name
- NCT03996356
- Testing
- No study intervention - observational study
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Antipsychotic Agents, Bipolar Disorder
Pharmacoepigenetics of Bipolar Disorder Treatment
Insulin is a hormone produced by the body to regulate blood sugar. Insulin resistance is a state when the body is not using insulin correctly, and more insulin is needed to maintain normal blood sugar.
- Trial name
- NCT02374996
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wayne State University
Schizophrenia, Tranquilizing Agents
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Conditions
- Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses
- Trial name
- NCT00294008
- Testing
- Risperdal Consta
- Volunteers
- 230 people
- Sponsor
- Janssen Korea, Ltd., Korea